Minocycline Susceptibility and tetB Gene in Carbapenem-Resistant Acinetobacter baumannii in Taiwan

Figures & data

Table 1 In vitro Antimicrobial Activity of Antimicrobial Agents Against 100 Genetically Unrelated Carbapenem-Resistant Acinetobacter baumannii Strains

Antimicrobial Agent	MIC50 (mg/L)	MIC90 (mg/L)	Range (mg/L)	CLSI Criteria^a			EUCAST Criteria^a
				%S	%I	%R	%S	%R
Ampicillin–sulbactam	64/32	>64/32	16/8 to >64/32	0	4	96	–	–
Amikacin	>32	>32	≤4 to >32	13	0	87	11	89
Ceftazidime	>16	>16	4 to >16	1	0	99	–	–
Cefepime	>16	>16	4 to >16	4	13	83	–	–
Ciprofloxacin	>2	>2	>2	0	0	100	0	100
Levofloxacin	>8	>8	4 to >8	0	6	94	0	100
Piperacillin–tazobactam	>64	>64	64 to >64	0	2	98	–	–
Imipenem	>8	>8	>8	0	0	100	0	100
Meropenem	>8	>8	>8	0	0	100	0	100
Colistin	0.25	1	<0.25 to >16	0	91	9	91	9
Minocycline	4	16	1 to 16	55	32	13	–	–
Tigecycline	2	4	1 to 16	0	0	0	0	100

Note: ^aCLSI (2021) and EUCAST (2022) criteria.

Abbreviations: CLSI, Clinical and Laboratory Standards Institute; EUCAST, European Committee on Antimicrobial Susceptibility Testing; MIC₅₀, 50% minimum inhibitory concentration; MIC₉₀, 90% minimum inhibitory concentration. S, susceptible; I, intermediate; R, resistant.

Figure 1 Distribution of minocycline minimum inhibitory concentrations (MICs) of the 100 carbapenem-resistant Acinetobacter baumannii strains.